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Abstract
We assessed changes in cell lines of varying p53 status after various fractionation regimens to determine if p53
influences gene expression and if multifractionated (MF) irradiation can induce molecular pathway changes.
LNCaP (p53 wild-type), PC3 (p53 null), and DU145 (p53 mutant) prostate carcinoma cells received 5 and 10 Gy
as single-dose (SD) or MF (0.5 Gy × 10, 1 Gy × 10, and 2 Gy × 5) irradiation to simulate hypofractionated and
conventionally fractionated prostate radiotherapies, respectively. mRNA analysis revealed 978 LNCaP genes differ-
entially expressed (greater than two-fold change, P < .05) after irradiation. Most were altered with SD (69%) and
downregulated (75%). Fewer PC3 (343) and DU145 (116) genes were induced, with most upregulated (87%, 89%)
and altered with MF irradiation. Gene ontology revealed immune response and interferon genes most prominently
expressed after irradiation in PC3 and DU145. Cell cycle regulatory (P = 9.23 × 10−73, 14.2% of altered genes,
nearly universally downregulated) and DNA replication/repair (P = 6.86 × 10−30) genes were most prominent in
LNCaP. Stress response and proliferation genes were altered in all cell lines. p53-activated genes were only
induced in LNCaP. Differences in gene expression exist between cell lines and after varying irradiation regimens
that are p53 dependent. As the duration of changes is ≥24 hours, it may be possible to use radiation-inducible
targeted therapy to enhance the efficacy of molecular targeted agents.
Translational Oncology (2013) 6, 573–585
Introduction
Prostate cancer is the most commonly diagnosed noncutaneous
malignancy in the United States [1]. Radiation therapy is the most
commonly employed treatment modality for prostate cancer in
North America [2]. It is typically administered in daily fractions
for approximately 8 weeks to allow for normal tissue repair and
repopulation between fractions, as well as tumor reoxygenation and
reassortment, but newer hypofractionation regimens using fewer
large daily doses deliver definitive prostate radiotherapy in as short
as 1 week.
Exposing mammalian cells to ionizing radiation results in DNA
damage and cellular responses, including cell cycle arrest, DNA
repair, and cell death [3]. These biologic effects, however, differ
following exposure to lower versus higher doses of irradiation
administered in a single fraction [3–6]. Ding et al. demonstrated
that in contrast to higher doses of 4 Gy, genes induced by lower
doses of 0.02 Gy generally regulate signal transduction, cell-to-cell
signaling, homeostasis, and cellular defenses [3]. In contrast, genes
controlling cell proliferation and apoptosis are more commonly induced
by higher irradiation doses above 0.5 Gy [3,5].
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The tumor suppressor protein p53 functions as a transcription fac-
tor and is a major regulator of cellular responses to DNA-damaging
agents such as ionizing radiation. p53 regulates cell cycle control and
checkpoints, cell differentiation, apoptotic pathways, cellular senes-
cence, and angiogenesis [7–10]. Following more limited DNA dam-
age from ionizing radiation, p53 can facilitate cellular repair through
cell cycle arrest and blocking in G1. For cells receiving more signif-
icant radiation-induced damage, p53 can promote apoptosis through
cell cycle checkpoints [11–13].
Mutations of the p53 gene are found in approximately half of
all human cancers [14] and can result in nuclear accumulation of
p53 protein, loss of p53 binding sites, and changes in the global con-
formation of p53 [10,15]. Abnormal p53 function can permit
mitosis or replication to proceed before radiation-induced DNA
damage is repaired [16,17]. This can increase the rate of radiation-
induced mutations, particularly after higher doses of radiation [16].
The function of the p53 gene, therefore, may in part determine
the sensitivity to damage induced by radiation therapy or systemic
therapy [11–13].
Cells that survive hypoxic or otherwise stress environments undergo
numerous molecular changes [18–21]. Repeated fractions of external
beam radiation therapy, as are administered for prostate cancer, repre-
sent such a stress and cause surviving cells to have altered phenotypes
that may differ in susceptibility and treatment response to subsequent
molecular targeted therapy. Additionally, fractionated irradiation makes
varying tumor cells more phenotypically similar [22]. As such, fraction-
ated irradiation may be able to induce potential molecular therapeutic
targets in irradiated cells. Therefore, in addition to the current roles
in prostate cancer of definitive, adjuvant, salvage, or palliative radio-
therapy, radiation therapy may allow for the induction of a target
for molecular targeted therapy rather than depending on the presence
of a mutation or the nontargeted use of small molecules and mono-
clonal antibodies [18]. The induction of genes by ionizing radiation
is dependent on the cell type, radiation dose, and time after irradiation
[3,23–26]. Selected effects of irradiation on PC3 and DU145 cells
following varying fractionation regimens have previously been reported
by the authors and are now expanded and compared to the results for
LNCaP cells [6].
More limited data describing how tumor p53 status influences
the tumor cell response to radiation therapy by varying radiation
fractionation regimens exist. To investigate the effects of irradiation-
induced p53-dependent or p53-independent pathways in response to
ionizing radiation, three prostate carcinoma cell lines with varying
p53 status were selected: LNCaP is wild type for p53, PC3 is p53
null, and DU145 is p53 mutant. The following three radiation doses
were used: 1) single high-dose irradiation of 5 and 10 Gy to compare
with the multifractionated (MF) regimens and which are consistent
with the large doses used in hypofractionated radiation therapy,
2) 1-Gy fractional low doses to understand the impact of multi-
fraction radiation (2 Gy had been compared to 1 Gy per fraction in
previous prostate experiments, as discussed in Materials and Methods
section), and 3) 0.5-Gy fractional low doses that produces very
little cell killing to simulate the dose that some tissues receive daily
with intensity-modulated radiotherapy (IMRT). Using gene ontol-
ogy classification and molecular pathway analysis, we assess changes
in prostate cancer cell lines of varying p53 status after various
irradiation fractionation regimens to determine if p53 status
influences gene expression and if MF irradiation can induce molecular
pathway changes.
Materials and Methods
Cells
LNCaP (p53 wild-type, androgen-dependent, highly differentiated),
PC3 [p53 null, androgen-independent, poorly differentiated, hemi-
zygous for chromosome 17p, mutation at codon 138 (C nucleotide
deletion→frame shift with a new in-frame stop at codon 169)], and
DU145 [p53 mutant, androgen-independent, moderately differen-
tiated, mutations at codons 223 (Pro→Leu) and 274 (Val→Phe)]
human prostate carcinoma cells [27] were obtained from American
Type Culture Collection (ATCC, Rockville, MD). Cells were main-
tained in ATCC RPMI 1640 medium that was supplemented with
antibiotics for all cell lines and glutamine and 10% ATCC FBS for
LNCaP cells. For microarray analysis, cells from passages P4, P7, and
P11 were used. For confirmation and protein extraction, cells from
passages P2 to P11 were used. Some data from PC3 and DU145 cells
have been previously reported [6] and were selectively used in this
manuscript for comparative purposes.
Radiation
Cells were plated onto T175 cell culture flasks (BD Falcon 175-cm2
flasks) [single-dose (SD) regimens: 2.0 × 106 cells for LNCaP and 1.6 ×
106 cells for PC3 and DU145;MF regimens: 1.0 × 106 cells for LNCaP
and 0.8 × 106 cells for PC3 and DU145]. The number of cells plated
for each cell line was experimentally designed to allow for cell conflu-
ence of approximately 50% at the time of first irradiation exposure
while also maintaining a confluence of under 70% in control flasks
and limiting varying nutrient conditions at the time of the last irradia-
tion exposure across varying fractionation regimens. After 24 hours,
cells were exposed to single or fractionated irradiation in an irradiator
using an Eldorado 8 60Co teletherapy unit (Theratronics International
Ltd, Ontario, Canada) housed in the Radiation Oncology Branch of
the National Cancer Institute, National Institutes of Health (Bethesda,
MD) that delivered dose rates between 150 and 180 cGy per minute.
Fractionation regimens were designed to allow for an assessment of
differential gene expression and the phenotype of surviving cells across
a variety of irradiation doses and fractionation schemas.
LNCaP cells were exposed to 5- or 10-Gy irradiation. Cells receiv-
ing 5 Gy were irradiated either as an SD (5 Gy × 1) or as an MF
course of 0.5 Gy twice daily for 5 days (0.5 Gy × 10). Cells receiving
10 Gy were irradiated either as an SD (10 Gy × 1) or as an MF
course of 1 Gy twice daily for 5 days (1 Gy × 10). PC3 and
DU145 cells had been irradiated as an additional MF course of 2 Gy
once daily for 5 days [6]. However, since few genes were uniquely dif-
ferentially expressed for the 2 Gy × 5 compared to 1 Gy × 10 regimens
in PC3 and DU145 cells [6] (and also based on the cost of these
experiments), the 2 Gy × 5 fractionation regimen was not administered
to LNCaP cells. For all MF regimens, fractions were administered at
least 6 hours apart. Unirradiated separate controls were maintained
for all SD and MF irradiation protocols.
Microarray Analysis
Microarray analysis and confirmation studies have previously been
described [6,28]. For LNCaP cells, total RNA was extracted and col-
lected at 24 hours after the final irradiation fraction using QIAshred-
der Spin Columns (Catalog No. 79654; Qiagen, Valencia, CA). For
PC3 and DU145 cells, total RNA was extracted and collected at
multiple time points 2, 6, and 24 hours after the final irradiation
doses [6]. All extracted RNA was purified with an RNeasy Mini
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Kit (Qiagen). The total RNA concentration was measured by spec-
trophotometry at A260/280. Agilent Bioanalyzer with the RNA6000
Nano Lab Chip (Agilent Technologies, San Francisco, CA) was used
to assess the quality of RNA samples. RNA isolates collected at
24 hours from irradiated and unirradiated samples from three dis-
tinct biologic replicates for all dose and fractionation regimens for
LNCaP, PC3, and DU145 cells were used to assess differences in
mRNA microarray analysis.
mRNA microarray analysis was performed using CodeLink Whole
Genome Bioarrays representing 55,000 probes [28]. These 30-mer
probes were designed to conserved exons across the transcripts of
targeted genes, and each probe represented well-annotated, full-
length, and partial human gene sequences from major public data-
bases. Scanned images from arrays (gridding and feature intensity)
were processed using CodeLink Expression Analysis software (GE
Healthcare, Buckinghamshire, United Kingdom). Data for each
feature on the array were analyzed with GeneSpring GX Software
(Agilent Technologies).
The raw intensity data for each gene on each array were normal-
ized to the median intensity of the raw values from that array. This is
a global normalization procedure that divides raw intensity values
from array by the 50th percentile value within each array. All data
were filtered for intensity values that were above background in at
least two of any set of three replicates for each time point and each
cell line within each irradiation fractionation regimen. Unsupervised
hierarchical clustering of all probes significantly above background
detection levels in at least one condition (irradiated or control) from
all three replicates defined expression profiles that were clustered by
biologic replicate treatments and not by technical conditions of the
experimental design. Analysis of variance was used to compare the
means of each condition (n = 3) to ensure reliable gene measure-
ments. Confirmation of microarray data was performed by real-time
polymerase chain reaction (PCR) and Western blot analysis, with all
confirmation samples also run in distinct biologic triplicates.
The data discussed in this publication have been deposited in
NCBI’s Gene Expression Omnibus and are accessible through GEO
Series Accession No. GSE36720 (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE36720).
Real-Time PCR
Alterations in genes that exhibited significant differential expres-
sion patterns (greater than two-fold change and P < .05) following
the different irradiation fractionation regimens or between different
cell lines were confirmed by real-time PCR using TaqMan Gene
Expression Assays, with the ABI PRISM 7500 Sequence Detection
System equipped with Sequence Detection System version 1.4.0 soft-
ware (Applied Biosystems by Life Technologies, Carlsbad, CA). All
forward and reverse primers and probes were designed and produced
by Applied Biosystems. Representative probes that were used included
OASL (Hs00984390_m1), IFI27 (Hs00271467_m1), and UBE1L
(Hs00163295_m1). Reagents for real-time PCR analysis were obtained
from Applied Biosystems. cDNAwas generated from 1 μg of RNA, and
PCR was performed using TaqMan Universal PCR Master Mix (Part
No. 4324018). Controls were processed using the same conditions
without an RNA template.
All numerical values were normalized to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH ) as an internal control gene and listed as the
average relative change in target genes of irradiated cells relative to
unirradiated control cells from three biologically distinct experi-
ments. Baseline mRNA levels of selected genes in control LNCaP,
PC3, and DU145 cells were determined, and relative differences
were calculated using the ΔΔCT method [28].
Ingenuity Pathway Analysis
Ingenuity Pathway Analysis (IPA, version 8.8; Ingenuity Systems,
Redwood City, CA) was used to assess the functional significance of
differentially expressed genes altered by irradiation. GenBank IDs
of all genes with at least a two-fold change and P < .05 were imputed
for network generation and pathway analyses and mapped to the
functional networks available in the Ingenuity Pathway Knowledge
Base, as previously described [28]. A score was determined for each
network, reflecting the negative logarithm of the P value based on the
chance that the focus genes were grouped in the network by random
chance. A score of 2 corresponds with a 1 in 100 chance that the
focus genes are grouped together by random chance. As such, scores
of 2 or higher indicate at least a 99% confidence that a true mo-
lecular relationship exists. Functional IPA was corroborated by an
independent gene ontology analysis, with enrichment of indi-
vidual functional gene categories determined by hypergeometric dis-
tribution P values obtained from comparison of the number of
genes differentially expressed to the number of annotated genes in
each category.
Data Analysis
Each data point represents the average ± SEM of three biologically
distinct experiments. Differences between the groups were evaluated
statistically by a two-tailed paired t test, and statistical significance
was defined as P < .05. Analysis of variance was used to compare
the means of each condition. For mRNAmicroarray analysis, a greater
than two-fold change (cutoff ratios of greater than 2.0 times or less
than 0.5 times) and a P value of <.05 relative to the respective control
were selected for this study.
Results
Global Gene Expression
Among all single-fraction and MF irradiation regimens, mRNA
microarray analysis revealed that 978 genes in LNCaP cells were
differentially expressed (greater than two-fold change and P < .05)
24 hours following irradiation. Most of these genes (75% across all
fractionation regimens at 24 hours) were downregulated. Down-
regulation occurred in 90% of all genes differentially expressed
Table 1. Number of Differentially Expressed Genes* in LNCaP Cells after SD and MF Irradiation.
Dose Comparison 10 Gy SD† 5 Gy SD 10 Gy MF‡ 5 Gy MF Genes in Common§
10 Gy × 1
581 491 – – 393
5 Gy × 1
1 Gy × 10
– – 462 128 117
0.5 Gy × 10
10 Gy × 1
581 – 462 – 166
1 Gy × 10
5 Gy × 1
– 491 – 128 23
0.5 Gy × 10
*Differentially expressed genes are greater than two-fold change and P < .05.
†SD, SD irradiation, either as 10 Gy × 1 or 5 Gy × 1.
‡MF, MF irradiation in 10 fractions, either as 1 Gy × 10 or 0.5 Gy × 10.
§Genes mutually upregulated or downregulated among both irradiation fractionation comparisons
are listed as Genes in Common.
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following SD irradiation, with down-regulation occurring in 88% of
differentially expressed genes after 10Gy × 1 and 92% after 5 Gy × 1. In
contrast, up-regulation occurred in 53%of differentially expressed genes
across MF regimens, including 46% after 1 Gy × 10 and 76% after 0.5
Gy × 10. Furthermore, more genes were differentially expressed fol-
lowing SD irradiation (69%) than MF irradiation (31%), with differ-
ential expression in 581 genes (10 Gy) and 491 genes (5 Gy)
administered in a single fraction, compared with 462 genes (1 Gy ×
10) and 128 genes (0.5 Gy × 10) in MF regimens (Table 1).
Somewhat more genes were differentially expressed with 10 Gy × 1
(581 genes) than 5 Gy × 1 (491 genes), and most of these genes
(393 genes) were mutually induced following both single-fraction
regimens (Table 1). While 462 genes were differentially expressed
following 1 Gy × 10 fractionation, significantly fewer genes were
induced with 0.5 Gy × 10 (128 genes). Nearly all genes (117/128,
91%) induced following 0.5 Gy × 10 were similarly induced following
1 Gy × 10. Including significantly upregulated (16 genes, 9.6%) and
downregulated (150 genes, 90.4%) genes, 166 genes in LNCaP cells
were mutually induced among the 10-Gy regimens (10 Gy × 1 and
1 Gy × 10). However, only 23 genes, including 6 upregulated
(26.1%) and 17 downregulated (73.9%) genes, were commonly differ-
entially expressed among the 5-Gy regimens (5 Gy × 1 and 0.5 Gy ×
10; Table 1).
In contrast to LNCaP, fewer total genes were induced in PC3
(343 genes) and DU145 (116 genes) cells among all irradiation frac-
tionation regimens at 24 hours. In PC3, 87 genes were induced fol-
lowing 10 Gy × 1 (67 upregulated, 20 downregulated), 136 following
2 Gy × 5 (129 upregulated, 7 downregulated), and 217 following
1 Gy × 10 (196 upregulated, 21 downregulated). In DU145, 63 genes
were induced following 10 Gy × 1 (55 upregulated, 8 downregulated),
29 following 2 Gy × 5 (26 upregulated, 3 downregulated), and 40
following 1 Gy × 10 (38 upregulated, 2 downregulated). Of differen-
tially expressed genes, up-regulation occurred in 86% of PC3 genes
and 89% of DU145 genes.
Unlike with LNCaP cells, where only 31% of differentially
expressed genes were induced by 1 Gy × 10 or 0.5 Gy × 10 multi-
fractionation regimens compared with 10 Gy × 1 and 5 Gy × 1 single-
fraction regimens, a higher proportion of differentially expressed genes
were induced following 2 Gy × 5 or 1 Gy × 10MF irradiation regimens
than 10 Gy × 1 or 5 Gy × 1 single-fraction regimens in PC3 (75%) and
DU145 (47%) cells. Fewer genes were mutually induced within cell
lines by single-fraction andMF regimens in both PC3 and DU145 cells
than in LNCaP cells. This is demonstrated for 10 Gy administered as
an SD or MF regimen in Figure 1.
Significant Functional Categories
All genes found to be differentially expressed (greater than two-
fold change and P < .05) after any irradiation fractionation protocol
at 24 hours for LNCaP, PC3, and DU145 cells were classified into
functional categories (Table 2). Enrichment of individual func-
tional gene categories was determined by hypergeometric distribution
P values obtained from the comparison of the number of genes differ-
entially expressed to the number of annotated genes in each category. A
complete list of genes from the significant functional categories assessed
by gene ontology that were differentially expressed by greater than
two-fold change and P < .05 is depicted in Table W1.
Gene ontology classification of genes differentially expressed at
24 hours after irradiation revealed that cell cycle regulatory genes
were most prominently differentially expressed in LNCaP cells but less
significantly altered or unaffected in PC3 and DU145 cells. DNA rep-
lication (10 Gy × 1: P = 3.01 × 10−52; 1 Gy × 10: P = 3.98 × 10−10) and
DNA repair (10 Gy × 1: P = 8.43 × 10−35; 1 Gy × 10: P = 6.54 × 10−6)
genes were among the next most prominently altered functional cate-
gories in LNCaP cells at 24 hours but were not significantly altered in
DU145 and PC3 cells. Immune response (PC3—10Gy × 1: P = 9.00 ×
10−4; 1Gy× 10:P = 5.19 × 10−20;DU145—10Gy× 1:P = 2.46 × 10−5;
1 Gy × 10: P = 1.55 × 10−3), interferon (PC3—10 Gy × 1: P = 2.05 ×
10−3; 1Gy× 10:P = 2.06 × 10−21;DU145—10Gy× 1:P = 9.79 × 10−4;
Figure 1. Venn diagrams depicting the number of upregulated and downregulated differentially expressed genes (greater than two-fold
change and P < .05) at 24 hours following exposure to 10 Gy as SD or MF (1 Gy × 10) irradiation regimens.
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1 Gy × 10: P = 1.96 × 10−4), and apoptosis (PC3—10Gy × 1: P = .099;
1 Gy × 10: P = 6.54 × 10−5; DU145—10 Gy × 1: P = .067; 1 Gy × 10:
P = 1.93 × 10−4) genes weremost prominently expressed after irradiation
in PC3 and DU145 cells but were less significantly altered in LNCaP
cells. Inflammatory response genes were only highly expressed in MF
regimens in PC3 cells.
At 24 hours following irradiation, stress response (LNCaP—10Gy ×
1: P = 3.15 × 10−14; 1 Gy × 10: P = 8.97 × 10−5; PC3—10 Gy × 1: P =
.01; 1 Gy × 10: P = 1.38 × 10−12; DU145—10 Gy × 1: P = 1.20 ×
10−4; 1Gy × 10:P = 4.34 × 10−4) and proliferation (LNCaP—10Gy × 1:
P=5.36 × 10−14; 1Gy×10:P =1.50 × 10−8; 0.5Gy×10:P=1.80 × 10−3;
PC3—10Gy×1:P= .03; 1Gy×10:P=1.84×10−5;DU145—10Gy×1:
P = 2.61 × 10−3; 1 Gy × 10: P = 2.17 × 10−3) genes were among the
most universally differentially expressed genes across all cell lines and
all fractionation regimens (Table 2). The several most significant func-
tional categories at 24 hours following irradiation for each cell line and
each featured fractionation regimen were similar for all assessed time
points before 24 hours (data not shown).
Relative changes in individual genes from several selected functional
categories for multiple irradiation fractionation regimens at 24 hours
for LNCaP, PC3, and DU145 cells were color coded to demonstrate
the expression patterns of those genes within each category. The heat
maps demonstrate that more cell cycle regularly genes (Figure 2A) were
differentially expressed in LNCaP cells than in PC3 or DU145 cells,
whereas immune response genes (Figure 2B) were more significantly
altered in PC3 and DU145 cells than in LNCaP cells. Furthermore,
the heat maps demonstrate that most differentially expressed genes were
upregulated in PC3 and DU145 cells but downregulated in LNCaP
cells. Qualitatively, these heat maps also demonstrate greater changes
in genes following SD irradiation for LNCaP cells (Figure 3), similar
changes with SD or MF irradiation for DU145 cells, and greater
changes with MF irradiation for PC3 cells (Figure 2).
Figure 3 depicts heat maps for three gene ontology categories,
namely, apoptosis, signal transduction, and DNA repair (Figure 3,
A–C , respectively), for LNCaP cells (the 0.5 Gy per fraction regimen
was only performed for LNCaP cells) at 24 hours. Although very
similar patterns were demonstrated following 5 and 10 Gy when
administered in a single fraction, patterns demonstrated after MF
regimens were significantly different from each other and from SD
regimens, particularly for 0.5 Gy × 10.
p53 Genes
p53-activated proapoptotic genes, including TP53I3 and
ANGPT2, were upregulated in LNCaP cells following all irradiation
fractionation regimens, whereas no up-regulation was observed in
these genes following any irradiation fractionation regimen at any time
point for either PC3 or DU145 cells. Twelve of the 102 p53 regulatory
genes (P = 2.95 × 10−7) assessed in the microarray analysis for LNCaP
were differentially expressed (greater than two-fold change and P < .05)
following irradiation (Table W2). Western blot analysis demonstrated
that transcriptional activation of both TP53I3 and ANGPT2 were seen
at the protein level for LNCaP cells (data not shown).
Immune Response Genes
Immune response genes at 24 hours were generally upregulated
following irradiation, particularly in PC3 cells, and particularly with
MF regimens [6]. Overall, heat maps demonstrate that immune re-
sponse genes at 24 hours were more significantly altered in PC3 and
DU145 cells than LNCaP cells (Figure 2). Among immune response
genes, IFI27, OASL, IFIT1, and IFIT3 were upregulated in all cell
lines. IFI27 was highly significantly upregulated following all MF
regimens in PC3 cells (fold change range of the various MF regi-
mens, 29.5-63.5 times). IFI27 was also upregulated in MF regimens
for DU145 and LNCaP cells, but no up-regulation was seen in any
Table 2. Gene Ontology Classification* among Differentially Expressed Genes for Various Prostate Cancer Cell Lines.
Category LNCaP PC3 DU145
10 Gy × 1 1 Gy × 10 10 Gy × 1 1 Gy × 10 10 Gy × 1 1 Gy × 10
Genes P Value Genes P Value Genes P Value Genes P Value Genes P Value Genes P Value
Cell cycle 128 3.75E−91† 65 5.61E−34 5 .02 9 .03 6 9.74E−04 1 NS
DNA replication 55 3.01E−52 17 3.98E−10 1 NS 3 NS 1 NS 0 NS
DNA repair 42 8.43E−35 12 6.54E−06 0 NS 0 NS 1 NS 0 NS
DNA binding 105 1.59E−26 59 3.68E−09 9 .02 26 1.11E−04 9 3.26E−03 5 .03
Cyclin 25 1.96E−22 13 6.76E−10 1 NS 1 NS 2 .01 0 NS
Response to stress‡ 45 3.15E−14 23 8.97E−05 5 .01 25 1.38E−12 7 1.20E−04 5 4.34E−04
Proliferation‡ 41 5.36E−14 28 1.50E−08 4 .03 14 1.84E−05 5 2.61E−03 4 2.17E−03
Histone 23 2.36E−12 16 3.51E−08 4 9.57E−04 3 NS 3 4.66E−03 0 NS
DNA damage 11 6.35E−08 5 3.43E−03 0 NS 3 .01 0 NS 2 2.21E−03
Ubiquitin 18 4.25E−04 6 NS 3 NS 10 3.04E−04 2 NS 2 NS
Transcription factor 29 6.70E−03 22 .03 3 NS 11 .05 6 6.28E−03 1 NS
Apoptosis 18 .01 12 NS 2 NS 13 6.54E−05 3 NS 5 1.93E−04
Signal transduction 28 NS§ 20 NS 7 .03 17 8.22E−03 3 NS 4 .05
Protease 4 NS 6 NS 2 NS 4 .04 5 2.22E−05 0 NS
Interferon 2 NS 5 .02 3 2.05E−03 19 2.06E−21 3 9.79E−04 3 1.96E−04
Immune response 8 NS 13 .03 6 9.00E−04 30 5.19E−20 7 2.46E−05 4 1.55E−03
Inflammatory response 1 NS 3 NS 1 NS 10 1.28E−08 2 .02 0 NS
*Enrichment of individual functional gene categories was determined by hypergeometric distribution P values obtained from comparison of the number of genes differentially expressed to the number
of annotated genes in each category. Selected gene categories are listed in order of descending statistical significance at 24 hours for the featured SD irradiation fractionation regimen (10 Gy × 1) for
LNCaP cells.
†The most significant functional category for each cell line and each featured fractionation regimen are depicted in gray shading and in bold. The second most significant are in bold, whereas the third
most significant are in bold italics.
‡Stress response and proliferation genes were among the most universally differentially expressed genes across all cell lines and all fraction regimens.
§NS, not significant (P ≥ .05).
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Figure 2. Heat maps depicting the expression patterns for (A) cell cycle regulatory genes and (B) immune response genes at 24 hours
following exposure to irradiation. LNCaP cells were exposed to 10 Gy × 1 (lane 1) and 5 Gy × 1 (lane 2) SD irradiation and 1 Gy × 10
(lane 3) and 0.5 Gy × 10 (lane 4) MF irradiation. PC3 and DU145 cells were exposed to 10 Gy × 1 (lane 1) SD irradiation and 2 Gy × 5
(lane 2) and 1 Gy × 10 (lane 3) MF irradiation. Orange to red indicates upregulated genes, and blue indicates downregulated genes. Heat
maps for PC3 and DU145 cells were adapted in part from John-Aryankalayil et al. [6].
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of the three cell lines following SD irradiation. Similarly, OASL was
highly significantly upregulated following all irradiation regimens in
PC3 cells, particularly among MF regimens (range, 7.2-12.3 times).
OASL was also upregulated in all SD regimens for DU145 cells and
all MF regimens for LNCaP cells. Both IFIT1 and IFIT3 were
upregulated in MF regimens for LNCaP and PC3 cells but only in
SD regimens in DU145 cells.
Cell Cycle Genes
Overall, 14.2% (139/978) of all differentially expressed genes in
LNCaP cells following irradiation were cell cycle regulatory genes,
the functional category with the most significant enrichment factor.
More cell cycle genes at 24 hours were differentially expressed in
LNCaP cells following SD regimens (128 genes for 10 Gy × 1,
P = 3.75 × 10−91) than MF regimens (65 genes for 1 Gy × 10,
Figure 3. Heat maps depicting the expression patterns for (A) apoptosis genes, (B) signal transduction genes, and (C) DNA repair genes
for LNCaP cells at 24 hours following exposure to SD 5 Gy × 1 (lane 1) and 10 Gy × 1 (lane 2) irradiation or MF 0.5 Gy × 10 (lane 3) and
1 Gy × 10 (lane 4) irradiation. Orange to red indicates upregulated genes, and blue indicates downregulated genes.
Table 3. Comparison of Differentially Expressed Representative Cell Cycle Regulatory Genes at 24 Hours among Various Prostate Cancer Cell Lines.
Symbol* Gene Name LNCaP PC3 DU145
10 Gy × 1 1 Gy × 10 10 Gy × 1 1 Gy × 10 10 Gy × 1 1 Gy × 10
Fold Change Fold Change Fold Change Fold Change Fold Change Fold Change
CDC20 Cell division cycle 20 homolog 0.04†, P = 2.21 × 10−5 0.23, P = .039 0.81, P = .014 1.50, P = .735 1.37, P = .083 0.99, P = .972
KIF20A Kinesin family member 20A 0.04, P = 2.70 × 10−3 0.30, P = .121 0.79, P = .205 1.09, P = .951 1.22, P = .036 1.15, P = .673
E2F2 E2F transcription factor 2 0.08, P = 3.43 × 10−3 0.42, P = .032 0.49, P = .023 0.43, P = .436 0.79, P = .039 1.06, P = .843
GINS2 GINS complex subunit 2 0.15, P = 1.13 × 10−3 0.31, P = .037 0.59, P = 1.79 × 10−3 0.51, P = .343 0.49, P = 2.83 × 10−3 0.88, P = .692
PIF1‡ PIF1 5′-to-3′ DNA helicase homolog 0.16, P = .031 0.35, P = .081 0.59, P = .059 1.22, P = .800 1.11, P = .521 0.94, P = .821
PIF1 PIF1 5′-to-3′ DNA helicase homolog 0.03, P = 1.03 × 10−4 0.17, P = .015 0.63, P = .033 1.04, P = .968 1.23, P = .144 0.87, P = .647
CCNB1 Cyclin B1 0.17, P = 5.60 × 10−4 0.33, P = .015 1.00, P = .975 1.09, P = .931 1.27, P = .039 1.06, P = .837
CCNE2 Cyclin E2 0.20, P = 6.70 × 10−3 0.48, P = .024 0.55, P = .042 0.62, P = .333 0.38, P = 3.15 × 10−3 1.05, P = .856
*All cell cycle regulatory genes differentially expressed (greater than two-fold change and P < .05) following every SD and MF irradiation regimen in LNCaP cells that were also differentially expressed in
any PC3 or DU145 fractionation regimen at 2, 6, or 24 hours following irradiation are included.
†Gray shading indicates genes significantly downregulated (ratio < 0.5 times and P < .05).
‡Two separate probes were used to assess PIF1 in the mRNA microarray analysis with the CodeLink Whole Genome Bioarrays, with values for each probe depicted. Good correlation was seen between
the probes. PIF1 is one of the rare genes in which multiple probes were used for its assessment.
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P = 5.61 × 10−34). In LNCaP cells, AURKA, AURKB, CCNB1,
CCNB2, CCNE2, CDC20, CDKN2C, CDKN3, E2F2, E2F8,
GINS2, KIF20A, PIF1, PLK4, and others were all significantly
downregulated after 10 Gy × 1, 5 Gy × 1, and 1 Gy × 10 irradiation
regimens, with the fold changes of selected cell cycle genes at
24 hours following 10 Gy × 1 and 1 Gy × 10 listed for all three cell
lines depicted in Table 3.
Cell cycle genes were much less significantly induced for SD regi-
mens for DU145 cells (P = 9.74 × 10−4) and were not significantly
induced for MF regimens (P = .490), whereas cell cycle gene induc-
tion in PC3 cells was modestly significant for SD (P = .016) and MF
(P = .031) regimens. Figure 2 depicts heat maps for cell cycle regu-
latory genes in LNCaP (10 Gy × 1 and 5 Gy × 1; 1 Gy × 10 and
0.5 Gy × 10) and PC3 and DU145 cells (10 Gy × 1; 2 Gy × 5 and
1 Gy × 10) 24 hours following SD or MF irradiation regimens.
Although 730 different genes were downregulated at any time
point following irradiation regimens in LNCaP cells, significantly
fewer genes were downregulated following irradiation in PC3 and
Table 4. Networks and Associated Functional Categories Identified by IPA for Various Prostate Cancer Cell Lines 24 Hours after Exposure to 10-Gy Irradiation Administered as an SD or MF Regimen
(1 Gy × 10).
Radiation Regimen IPA Score Focus Molecules Function
LNCaP
10 Gy × 1 56* 32† Cell cycle, cellular assembly/organization, DNA replication/recombination/repair
47 29 DNA replication/recombination/repair, cell cycle, cellular assembly/organization
47 29 Cancer, gastrointestinal disease, genetic disorder
41 27 DNA replication/recombination/repair, cell cycle, cancer
36 25 Cell cycle, cancer, gastrointestinal disease
35 26 Cellular assembly/organization, DNA replication/recombination/repair, cell cycle
33 23 Nucleic acid metabolism, small molecule biochemistry, cancer
32 22 Cell cycle, DNA replication/recombination/repair, cell signaling
32 22 Cancer, genetic disorder, respiratory disease
31 23 Cell cycle, cellular assembly/organization, DNA replication/recombination/repair
28 21 Cell cycle, cellular movement, DNA replication/recombination/repair
28 23 DNA replication/recombination/repair, infection mechanism, cell cycle
23 18 Cell cycle, cellular development, embryonic development
22 17 Developmental disorder, genetic disorder, carbohydrate metabolism
22 17 Organismal injury/abnormalities, cell signaling, carbohydrate metabolism
22 17 Immunologic disease, inflammatory disease, neurologic disease
20 16 Organ morphology, gene expression, inflammatory response
17 14 Cancer, dermatological diseases/conditions, neurologic disease
15 13 Cell cycle, embryonic development, tissue development
14 13 Genetic disorder, metabolic disease, DNA replication/recombination/repair
1 Gy × 10 55 30 Cellular assembly/organization, cell cycle, cancer
44 27 Cell cycle, cardiovascular system development/function, organismal development
37 23 Cardiovascular disease, developmental disorder, cellular development
36 23 Gene expression, developmental disorder, genetic disorder
35 24 Cancer, genetic disorder, respiratory disease
29 19 Cell signaling/interaction, cellular assembly/organization, cellular function/maintenance
28 19 Cell cycle, cell death, drug metabolism
27 19 Cancer, endocrine system disorders, genetic disorder
27 19 Cancer, genetic disorder, respiratory disease
24 17 Cell morphology, cellular assembly/organization, nervous system development/function
23 18 Cellular development, reproductive system development/function, cell cycle
21 15 Cell cycle, DNA replication/recombination/repair, gene expression
17 13 Cell signaling, carbohydrate metabolism, small molecule biochemistry
17 13 Cardiac arrythmia, cardiovascular disease, organismal injury/abnormalities
15 13 Lipid metabolism, molecular transport, small molecule biochemistry
DU145‡
10 Gy × 1 None – –
1 Gy × 10 32 13 Cancer, cellular movement, reproductive system development/function
10 5 Cancer, cell morphology, cell signaling
PC3‡
10 Gy × 1 45 19 Cell-to-cell signaling/interaction, dermatological diseases/conditions, lipid metabolism
30 14 Antigen presentation, cancer, cardiovascular disease
20 10 Cancer, cellular movement, cardiovascular system development/function
1 Gy × 10 57 28 Antigen presentation, antimicrobial response, cell-mediated immune response
36 20 Carbohydrate metabolism, small molecule biochemistry, cardiovascular disease
32 18 Cellular development, genetic disorder, inflammatory disease
32 18 Carbohydrate metabolism, hepatic system development, small molecule biochemistry
27 16 Cellular development, hematological system development/function, hematopoiesis
23 14 Genetic disorder, hematological disease, metabolic disease
19 13 Cell morphology, cellular development, neurologic disease
17 11 Cell signaling, molecular transport, vitamin/mineral metabolism
11 8 Hematological disease, cancer, cell death
*IPA score refers to statistical significance, with all genes with at least a two-fold change and a P < .05 imputed for network generation and pathway analyses and mapped to the functional networks
available in the Ingenuity Pathway Knowledge Base. A score was determined for each network reflecting the negative logarithm of the P value based on the chance that the focus genes were grouped in the
network by random chance. Only scores ≥ 10 are depicted.
†Focus molecules indicate the number of genes that could be mapped to molecules out of a possible 35 molecules in each network.
‡Adapted in part from John-Aryankalayil et al. [6].
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DU145 cells. As such, only three genes were mutually down-
regulated among all three cell lines. PIF1 (5′-to-3′ DNA helicase that
negatively regulates telomerase, a reverse transcriptase that maintains
telomere length), KIF20A (microtubule-dependent molecular motor
that plays important roles in intracellular transport and cell division,
is potentially involved in mitosis, and facilitates myosin and kinesin-
mediated processes), andCCNB1 (encodes a regulatory protein involved
in mitosis, with a gene product complex expressed predominantly
during G2/M phase of the cell cycle) were downregulated in all SD
irradiation regimens for all three cell lines but only in LNCaP cells fol-
lowing MF irradiation. While the down-regulation of PIF1, KIF20A,
andCCNB1 following irradiation persisted at 24 hours for LNCaP cells,
the down-regulation seen at 2 and 6 hours following irradiation for PC3
and DU145 cells did not remain significant at 24 hours. Furthermore,
the magnitude of down-regulation for LNCaP cells was significantly
greater for SD than MF regimens, particularly for KIF20A (fold change
range of various SD regimens, 0.04-0.06 times).
Ingenuity Pathway Analysis
Genes significantly altered following irradiation (greater than two-
fold change and P < .05) were mapped to the functional networks in
the IPA database and ranked by score to further assess the effects of
varying irradiation fractionation regimens at 24 hours following the
completion of irradiation for each cell line of varying p53 status
(Table 4). Overall, IPA revealed significant differences between SD
and MF irradiation regimens. When assessing all MF regimens, path-
ways in common between all three cell lines included cancer, cell sig-
naling, antigen presentation, and cell morphology.
However, other notable differences were seen across cell lines with
varying p53 status. In LNCaP cells, cell cycle and cellular assemble
and organization functions predominated following SD and MF irra-
diation. No appreciable differences in networks were observed be-
tween the 5- and 10-Gy SD regimens. However, fewer networks
with an IPA score of greater than 10 were identified following MF
regimens in LNCaP cells, particularly following 0.5 Gy × 10, which
was found to have networks functionally more uniquely associated
with cellular movement, connective tissue development and function,
hepatic system disease, and gastrointestinal disease (Table W3). In
contrast, a greater number of networks were observed with MF irradi-
ation in PC3 cells. Networks functionally related to immune response,
including antigen presentation, cell-mediated immune response, anti-
microbial response, and infection mechanism, were observed after all
fractionation regimens in PC3 cells, whereas cell-to-cell signaling was
unique to SD irradiation. Few networks with an IPA score of greater
than 10 were identified following any fractionation regimen in DU145
cells. Similar finding with the miRNA expression patterns in DU145
cells after SD and fractionated irradiation in comparison to LNCaP and
PC3 cells were also identified [29].
Confirmation of Microarray Data
The relative expressions of selected genes following irradiation for
LNCaP, PC3, and DU145 cells identified by microarray analysis
were confirmed by real-time PCR and/or Western blot analysis.
An extensive demonstration of real-time PCR confirmation for
PC3 and DU145 cells for multiple fractionation regimens has previ-
ously been reported [6]. Similar confirmation studies were conducted
for LNCaP, with selected real-time PCR data reported in Table 5
representing the average ± SEM of three biologically distinct experi-
ments. Among genes selected for confirmation by real-time PCR
(14 genes), 100% correlation was observed with microarray data
for all three cell lines and for all irradiation fractionation regimens.
Western blot analysis confirmed that the up-regulation or down-
regulation of selected representative genes was also confirmed at the
protein level (data not shown).
Discussion
This study demonstrated that the manner in which irradiation is
delivered, either as an SD or MF regimen, can dramatically influence
the gene expression pattern induced by ionizing radiation. The pheno-
type of malignant cells surviving MF irradiation regimens differs from
the starting cell population and from cells exposed to a single higher dose
of irradiation. Among the three MF regimens investigated, 1 Gy × 10
induced more genes and had greater magnitudes of gene expression
changes than either 0.5 Gy × 10 or 2 Gy × 5. However, gene induction
was demonstrated even after irradiation fractions as low as 0.5 Gy
(TableW4), a fraction size inwhichmuch of the cell population survives
each fraction. Changes demonstrated in this study following 0.5-Gy
fractions, therefore, may in part be attributable to an adaptive response
or stress response [30].
This study also demonstrated that gene expression patterns sig-
nificantly differed between cell lines of varying p53 status, as is in
keeping with the findings of prior studies [23,30,31]. Although
the regulation of p53-dependent genes is multifactorial, this study
demonstrated that p53-activated genes were induced only in p53
wild-type LNCaP cells, whereas DU145 and PC3 cells did not result
in the expression of p53-related genes following any irradiation frac-
tionation regimen, an expected finding in tumor cells with mutated
and null p53, respectively. This study also demonstrated that the
number of genes differentially expressed and the proportion of genes
Table 5. Validation of Microarray Data*.
Gene Relative Gene Expression LNCaP PC3† DU145†
10 Gy × 1 1 Gy × 10 10 Gy × 1 1 Gy × 10 10 Gy × 1 1 Gy × 10
OASL Microarray 1.4 ± 0.1 3.4 ± 0.3 3.1 ± 0.3 12.3 ± 2.4 3.7 ± 0.3 2.1 ± 0.5
PCR 2.1 ± 0.2 5.1 ± 1.1 4.4 ± 0.9 43.1 ± 2.7 5.7 ± 0.4 4.1 ± 0.5
IFI27 Microarray 1.4 ± 0.1 3.7 ± 0.6 1.4 ± 0.2 63.5 ± 22.3 0.9 ± 0.2 2.5 ± 0.8
PCR 1.5 ± 0.4 6.9 ± 0.9 2.1 ± 0.3 544.8 ± 10.5 1.5 ± 0.3 2.0 ± 0.3
UBE1L Microarray 1.6 ± 0.3 3.5 ± 0.5 2.4 ± 0.2 3.3 ± 0.8 2.1 ± 0.3 7.9 ± 5.3
PCR 1.7 ± 0.3 4.3 ± 0.8 1.7 ± 0.1 6.3 ± 0.8 2.5 ± 0.4 4.0 ± 0.6
*Relative expression of selected genes identified by microarray analysis were validated by real-time PCR. LNCaP, PC3, and DU145 cells were irradiated with SD (10 Gy × 1) and MF (1 Gy × 10)
irradiation. Each data point represents the average ± SEM of three biologically distinct experiments.
†Adapted in part from John-Aryankalayil et al. [6].
Translational Oncology Vol. 6, No. 5, 2013 p53 Influences Prostate Cancer mRNA Expression Simone et al. 581
upregulated or downregulated following irradiation differed greatly
among cell lines of varying p53 status. Following irradiation, LNCaP
cells demonstrated the greatest number of genes differentially expressed
(or altered), particularly for cell cycle regulatory genes. Genes were also
more likely to be downregulated and altered by SD regimens in LNCaP
cells than in the p53 null and mutant cell lines. p53 mutant DU145
cells showed the fewest number of genes altered following irradiation.
This may be due, in part, to the higher surviving fractions for DU145
cells following SD and MF irradiation regimens. The majority of genes
differentially expressed in p53 null PC3 cells, like DU145 cells, were
upregulated. Genes induced in PC3 cells were proportionately the most
likely to regulate immune response and be altered following MF regi-
mens. In fact, immune response genes across MF regimens at 24 hours
were the most significantly altered functional category in PC3 cells (P =
6.72 × 10−11), and 30 immune response genes were differentially
expressed (greater than two-fold change and P < .05) of the 865 immune
response genes assessed on mRNA microarray analysis.
When assessing changes following irradiation across cell lines, a
higher proportion of genes were downregulated following SD regi-
mens than MF regimens. This was particularly true for LNCaP cells,
in which down-regulation occurred in 90% of all genes differentially
expressed following SD irradiation. This is in keeping with previous
finding that higher biologically equivalent doses result in more gene
down-regulation than up-regulation [30,31].
Cell cycle regulatory genes at 24 hours were most prominently dif-
ferentially expressed in LNCaP cells (SD and MF aggregate P = 9.23 ×
10−73) but were not significant when aggregated across all fractionated
regimens in PC3 and DU145 cells (P ≥ .05 for both). Radiation-
induced DNA damage induces numerous cellular responses, includ-
ing cell cycle arrest. Irradiation of cells that express wild-type p53, such
as LNCaP cells, results in an accumulation of cells in G1 [13]. In
contrast, we have previously demonstrated that PC3 and DU145 cells
show significant G2/M arrest in response to SD but notMF irradiation,
with appreciable decrease in G1 [6]. After cell cycle regulatory genes,
DNA replication and repair genes were most prominently differentially
expressed in LNCaP cells (aggregate P = 6.86 × 10−30). Previous studies
have suggested that regulation of DNA repair may be induced at early
time points following irradiation [32].
It is possible that irradiation caused a suppression of cell cycle and
repair mechanisms in LNCaP cells. As more cell cycle genes were
differentially expressed following irradiation in LNCaP cells than
PC3 or DU145 cells, this could account for the higher proportion
of genes differentially downregulated in LNCaP cells. Although the
effects of irradiation were demonstrated to vary across cell lines of
varying p53 status, homeostatic regulation allowed for some cell repair
and propagation across the varying fractionation regimens and cell
lines. A major target of radiation-induced type I interferon is the
hematopoietic compartment. Shared mechanisms of homeostasis across
cell lines may be through hormonal release or diffusion. Furthermore,
an emerging theory of radiation homeostasis hypothesizes that low
doses of ionizing radiation can be beneficial by stimulating the activa-
tion of repair mechanisms that protect against cell death that are not
activated in absence of ionizing radiation. Should this theory prove
accurate and refute the linear no threshold model, such effects could
occur following our 0.5-Gy MF regimen.
A minority of differentially expressed genes were similarly upregu-
lated or downregulated following irradiation in all cell lines of varying
p53 status when stringent parameters for significance were applied to
our microarray results (greater than two-fold and P < .05). Several
immune response genes were mutually upregulated in all cell lines,
including IFI27, OASL, IFIT1, and IFIT3, whereas few cell cycle
regulatory genes were mutually downregulated, including PIF1,
KIF20A, and CCNB1. Additionally, UBE1L, which is involved in
apoptosis and cell growth regulation, and HIST1H2BD, which is a
regulator of nucleosome structure, were upregulated in all cell lines.
UBE1L and HIST1H2BD were upregulated following SD and MF
regimens in PC3 cells, SD regimens in DU145 cells, and MF regi-
mens in LNCaP cells. Such genes that have been demonstrated in
this study to be commonly differentially expressed across cell lines
of varying p53 status following MF irradiation regimens may serve as
potential ideal targets for molecular therapy and warrant more investi-
gation, particularly upregulated genes highly significantly altered,
including IFI27, OASL, and UBE1L. It is possible that the very highly
significant up-regulation seen in IFI27 in multifraction regimens in
PC3 cells is related to our findings that STAT1 was most prominently
altered in PC3 cells after MF irradiation and not after SD irradiation or
in LNCaP or DU145 cells, as STAT1 is upstream in the interferon
signaling pathway and known to physically associate with the IFI27
promoter. Further assessment of this association is needed if IFI27 is
used for molecular therapy development.
Among PC3 and DU145 cells, immune response genes were most
significantly altered following irradiation. This is in keeping with pre-
vious reports demonstrating that the efficacy of radiation therapy is
influenced by innate and adaptive immunity and may be significantly
dependent on the type I interferon family of cytokines. Furthermore,
irradiation can result in an increase in intratumoral production of
interferon-β, increase production of inflammatory cytokines, and
enhance tumor-specific immune responses [33]. Numerous immune
response genes were mutually differentially expressed between PC3
and DU145 cells [6], and nearly half of the genes mutually altered
in all three cell lines were immune response genes. Most of these
genes were more influenced by MF than SD irradiation regimens,
as has been shown in previous studies [6,22]. As with the other func-
tional categories, many more immune response genes would have
been found to be mutually differentially expressed between PC3
and DU145 cells if a greater than two-fold cutoff had been used
as the sole stratification criteria, irrespective of P value, particularly
with MF regimens. When using more stringent criteria of both a
greater than two-fold cutoff and a P value < .05, fewer genes were
identified as mutually differentially expressed due to intragroup vari-
ation among biologic triplicates that increased the P value to ≥.05
in several genes that were differentially expressed by greater than
two-fold.
This study suggests that MF irradiation can elicit a common gene
response across cell lines with varying p53 phenotypes, particularly
for immune response, stress response, and proliferation genes. This
is of significance since such radiation-induced expression of immune
response genes that was demonstrated in this study may enhance
tumor-specific immune responses and render tumor cells more sus-
ceptible to molecular targeted therapy through endogenous priming
mechanisms and potential increased efficacy of immune-related
therapy [33]. As such, radiation may act synergistically with immuno-
therapy to enhance immune response, inhibit immune suppression,
or alter tumor cell phenotypes, making tumors more susceptible to
immune-mediated killing [33,34]. Additionally, stress response and pro-
liferation genes were among the most universally differentially ex-
pressed genes in this study. Although to a lesser extent following
0.5 Gy × 10 irradiation (stress response: P = .026; proliferation:
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P = .002), these genes were highly significantly altered follow-
ing both SD and MF irradiation regimens in LNCaP cells.
These genes were similarly differentially expressed following
SD and MF regimens in DU145 cells, and they were altered to a
much greater extent following MF regimens in PC3 cells. Many of
the stress response and proliferation genes differentially expressed
following 1 Gy × 10 irradiation in PC3 cells were mutually altered
following the same regimen in LNCaP cells.
Fraction sizes of 0.5 and 1 Gy that were tested in this study reflect
cellular response when there is repeated irradiation delivered with
little cell killing. Pronounced gene expression was still achieved fol-
lowing 1-Gy MF regimens in LNCaP cells that largely mirrored
changes observed for single-fraction regimens. However, a dramati-
cally different expression profile was observed in LNCaP cells follow-
ing repeated administration of 0.5-Gy irradiation that was most
similar to the profiles observed following MF regimens in PC3 and
DU145 cells, with immune response, interferon, and proliferation
genes most affected. These changes may, in part, be attributable to
an adaptive or stress response [30]. Furthermore, with these low-dose
fractionated regimens, exposure to repeated doses of sublethal irradi-
ation could induce an adaptive phenotype change that is preserved
across generations from both irradiated and nonirradiated bystander
cells [35].
Little clinical data exist using low fraction sizes below conventional
1.8- to 2.0-Gy fraction doses to treat prostate carcinoma. Regional
normal tissues, tumor cells that have regionally metastasized beyond
the radiation therapy planning target volume or field edge, and tumor
cells that are located in a relative low-dose region within the clinical
target volumemay receive radiation doses of significantly less than 1.8 to
2.0Gydaily, as were delivered in this study, particularly withwidespread
current use of IMRT to treat prostate cancer. Indeed, it is conceivable
that the field-within-a-field approach with IMRTmay induce tumor cell
heterogeneity [35].
Administration of low fraction sizes for therapeutic effect, how-
ever, has been assessed with hyperfractionated radiotherapy and for
chemotherapy sensitization. Compared with standard fractionation,
hyperfractionation to an isoeffective tumoricidal dose may lower
the rates of acute and late genitourinary and gastrointestinal toxicities
without compromising treatment efficacy [36,37]. However, clinical
applications of hyperfractionation have been limited due to the cal-
culated low α/β ratio of prostate adenocarcinoma that would favor
hypofractionated radiotherapy [37]. Low-dose fractionated radiation
therapy has also been tested as a chemotherapy sensitizer in limited
clinical studies. The first clinical application of this concept involved
the administration of 80-cGy fractions on the first and second days
of chemotherapy cycles with paclitaxel and carboplatin in patients
with locally advanced squamous cell carcinoma of the head and neck
[38]. Low-dose fractionated radiation therapy has also been evaluated
clinically with promising results using 60- to 70-cGy fractions with
gemcitabine for pancreatic cancer [39] and 60-cGy fractions with
docetaxel for ovarian cancer [40]. Akin to its use as a chemopotentiator,
this work serves as a basis for pursuing fractionated radiotherapy to
induce targets for molecular targeted therapy. Further investigation,
however, is needed to determine if the dose per fraction can be tailored
to achieve a desired radiobiologic effect.
It is of no surprise that gene expression following irradiation was
found in this study to be dependent on p53 status. p53 gene muta-
tions and nuclear accumulation of p53 protein have also been shown
to result in more aggressive tumor phenotypes in prostate, bladder,
lung, colorectal, brain, cervical, breast, and head and neck malig-
nancies [41–44]. Multiple studies have demonstrated inherent radio-
biologic differences or poorer outcomes in patients undergoing
definitive radiation therapy for prostate cancer with p53 gene muta-
tions. p53 mutations are associated with increased prostate-specific
antigen (PSA) serum level, advance clinical stage, higher tumor
grade, decreased response to hormonal therapy, decreased response
to radiation therapy, increased rates of biochemical and clinical failures
following definitive radiation therapy, increased risk of metastasis, and
decreased survival [45–49].
The multi-institutional Radiation Therapy Oncology Group 8610
trial of 471 patients assessed p53 status and prognosis in prostate
cancer, and 18% of patients had abnormal p53 protein expression
[50]. Independent of Gleason score and clinical stage, abnormal
p53 expression was associated with decreased progression-free survival
(P = .03), decreased overall survival (P = .02), and increased distant
metastases (P = .04), particularly among patients receiving both radi-
ation therapy and hormonal therapy (P = .001), potentially suggesting
that the apoptotic effects of radiation therapy and/or hormonal ther-
apy are blocked in patients with p53 mutations.
The multi-institutional Cancer and Leukemia Group B 9682 trial
demonstrated abnormal p53 expression correlated with higher rates
of PSA failure at 5 years following radiation therapy (33% vs 18%,
P = .008) in 180 patients with prostate carcinoma, even after adjust-
ing for tumor grade, PSA level, stage, and hormonal therapy [51].
Radiation Therapy Oncology Group 9202 enrolled 777 patients
with clinically localized prostate carcinoma, of which 21.6% had
abnormal p53 expression [52]. Patients with abnormal expression
had nearly twice the rates of cause-specific mortality [hazard ratio
(HR) = 1.89, P = .014] and distant metastasis (HR = 1.72, P =
.013). The survival detriment with p53 overexpression was greatest
for patients receiving radiation therapy with short-term versus long-term
hormonal therapy (HR = 2.43, P = .0044). p53 mutations have also
been correlated with poorer surgical outcomes [53] and chemoresis-
tance or decreased responses to chemotherapy [54,55].
The current study suggests that apoptosis may contribute to pros-
tate cancer cell death, with the degree of this contribution differing
across cell lines of varying p53 status. Apoptosis is one mechanism
through which radiation therapy, with or without hormonal therapy,
is believed to function to eradicate prostate cancer cells [56]. As has
been demonstrated with other genitourinary malignancies, the ability
of ionizing radiation to induce p53-dependent apoptosis in malig-
nant cells is impaired in tumors with mutated p53 [57]. To date,
novel molecular treatment strategies aiming to reconstitute wild-type
p53 function in mutant p53-expressing prostate tumors to improve
radiation sensitivity, such as through the use of adenovirus vectors,
have had mixed results [58,59].
Therefore, the use of novel targeted agents represents one potential
method of circumventing this interruption in the apoptotic pathway.
Cell survival analysis across cell lines to determine the influence of
p53 status on cell survival following irradiation has demonstrated
the greatest radiosensitivity among LNCaP cells and the least radio-
sensitivity among DU145 cells [29]. Further study modulating p53
is needed to assess the contribution of apoptosis toward cellular death
in these cell lines following irradiation.
To identify gene expression patterns and changes in molecular
pathways, further study is underway to assess radiation-induced dif-
ferential gene expression through miRNA, mRNA, protein array,
and phosphorylation changes at the proteomic level with additional
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cancer cell lines exhibiting both normal and dysfunctional p53. As
p53 null PC3 cells have previously been reported to have similar
survival to cells with a normal p53 gene following SD irradiation
but decreased survival following MF irradiation [45], cell cycle stud-
ies across cell lines with varying p53 status are currently underway.
Molecular targeted drug regimens in combination with reconstitut-
ing wild-type p53 function will also be a focus of our laboratory. The
prominence of differentially expressed immune response genes fol-
lowing multifraction irradiation regimens for p53 defective and null
cells suggests that prostate tumors with mutant p53 may be amenable
to MF radiotherapy plus immunotherapy, which is worthy of further
study. We will also assess additional irradiation fractionation patterns,
particularly with lower doses per fraction and potentially lower dose
rates, as the fractionation regimen employed may be chosen to opti-
mize induction of certain pathways amenable to molecular targeted
therapy. This ongoing work will further advance our investigation
of the novel approach of inducing drug susceptibility in cells that
survive repeated stresses from MF irradiation.
Although the increasing use of IMRT and image-guided radiation
therapy for prostate cancer have reduced the high-dose irradiation
damage to adjacent normal tissues, thus allowing for radiation dose
escalation and improved biochemical relapse-free survival rates,
IMRT also results in the exposure of more normal tissue to any irra-
diation dose. In conjunction with the studies on prostate cancer cells
presented here, we are currently evaluating the effects of SD and MF
irradiation exposure on gene expression and miRNAs in human cor-
onary artery endothelial cells (Palayoor et al., in preparation). More
akin to that seen in PC3 cells than LNCaP cells, fractionated irra-
diation exposure results in more robust gene and miRNA changes
in human coronary artery endothelial cells compared with SD irradi-
ation, suggesting differences in response between wild-type p53-
harboring normal cells and tumor cells.
This study and our prior investigations [6,22] demonstrate that
the timing of irradiation, in addition to the dose per fraction, can
be selected to optimize desired molecular phenotypic changes. It is
also likely that MF irradiation regimens alter upstream or down-
stream molecules in the signaling pathway of known target mole-
cules. Our previous [6,22] and present studies demonstrate that
cells surviving a repeated irradiation stress are phenotypically altered
in a manner that is dependent on the fractionation regimen employed.
The use of MF irradiation regimens, therefore, may be suitable for
focused biology with combined modality therapy by altering pheno-
types of cells surviving such MF regimens, thus enhancing tumor cell
killing and reducing normal tissue toxicity [34,60].
While previous studies have assessed gene expression following
shorter time points after irradiation, the phenotypic changes demon-
strated in this study were durable, with continued differential gene
expression evident at least 24 hours following irradiation. Therefore,
radiation-induced changes may be sufficiently stable to allow for
molecular targeting of these phenotypic changes and can logistically
be more easily integrated into existing molecular targeted drug regi-
mens. Although further study is needed to determine if a radiation-
inducible pathway in the absence of a mutated pathway is truly stable
and druggable, it may be possible to use radiation as a stress response
to induce targets for molecular targeted therapy and enhance immu-
notherapy rather than only depending on the presence of mutations,
thus enhancing efficacy of targeted agents and exploiting the synthetic
lethal concept [61] and non-oncogene addiction approaches to cancer
treatment [62].
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